China SXT Pharmaceuticals, Inc. (SXTC) News

China SXT Pharmaceuticals, Inc. (SXTC): $1.25

-0.11 (-8.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SXTC News Items

SXTC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SXTC News From Around the Web

Below are the latest news stories about China SXT Pharmaceuticals Inc that investors may wish to consider to help them evaluate SXTC as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning!

William White on InvestorPlace | July 20, 2021

China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that a 1 for 4 reverse split of its ordinary shares was approved by the Company's board of directors on January 23, 2021 and is expected to become effective on February 19, 2021, China SXT's ordinary shares is expected to begin trading on a split-adjusted basis when the market opens on February 22, 2021.

Yahoo | February 19, 2021

Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | November 27, 2020

NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that on September 8, 2020, it received notification from NASDAQ granting the Company an additional 180-day period, or until March 8, 2021, to regain compliance with NASDAQ's minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550(a)(2) (the "Rule").

Yahoo | September 9, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5802 seconds.